Compare Ascendis Pharma A/S (ASND) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF nearer its low. Which is the better fit depends on your goals.
| ASND | FLRN | |
|---|---|---|
Market Cap | $16.78B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $30.86 |
52-Week Low | $189.74 | $30.65 |
Enterprise Value | $17.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
FLRN trades at $30.76 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock lacks key valuation metrics (P/E, P/S, P/B) in current data. Recent dividend payments of $0.11 suggest stable income distribution, but fundamental analysis is limited without updated financial statements.
Outlook remains cautious due to bearish technical signals and incomplete fundamental data. Investment opportunity hinges on upcoming financial disclosures to assess profitability and growth. Primary risks include market volatility and reliance on future earnings reports for valuation clarity. Investors should await Q2 2026 results for deeper insight.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
